INV vs NTLA

For growth investors, Intellia Therapeutics, Inc.

(NTLA) is the stronger pick with 16. 9% revenue growth year-over-year, versus 9. 2% for Innventure, Inc. (INV). Analysts rate Intellia Therapeutics, Inc. (NTLA) a "Buy" — based on 39 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Innventure, Inc.

(INV) delivered a total return of -37. 9%, compared to -79. 8% for Intellia Therapeutics, Inc. (NTLA). Over 10 years, the gap is even starker: INV returned -30. 0% versus NTLA's -41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Intellia Therapeutics, Inc.

(NTLA) is the lower-risk stock at 2. 21β versus Innventure, Inc. 's 2. 81β — meaning INV is approximately 27% more volatile than NTLA relative to the S&P 500. On balance sheet safety, Innventure, Inc. (INV) carries a lower debt/equity ratio of 4% versus 14% for Intellia Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Intellia Therapeutics, Inc.

(NTLA) is pulling ahead at 16. 9% versus 9. 2% for Innventure, Inc. (INV). On earnings-per-share growth, the picture is similar: Intellia Therapeutics, Inc. grew EPS 27. 4% year-over-year, compared to -143. 1% for Innventure, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Intellia Therapeutics, Inc.

(NTLA) is the more profitable company, earning -609. 9% net margin versus -64. 1% for Innventure, Inc. — meaning it keeps -609. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTLA leads at -651. 7% versus -63. 2% for INV. At the gross margin level — before operating expenses — NTLA leads at 76. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, INV (0.

2% yield) pays a dividend. NTLA does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innventure, Inc.

(INV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INV: -30. 0%, NTLA: -41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (INV (Financial Services) and NTLA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: INV is a small-cap quality compounder stock; NTLA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.